Symbols / LFCR
LFCR Chart
About
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It offers services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 279.50M |
| Enterprise Value | 436.09M | Income | -44.36M | Sales | 128.87M |
| Book/sh | 0.04 | Cash/sh | 0.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 406 | IPO | — |
| P/E | — | Forward P/E | -8.67 | PEG | — |
| P/S | 2.17 | P/B | 207.22 | P/C | — |
| EV/EBITDA | -109.60 | EV/Sales | 3.38 | Quick Ratio | 1.46 |
| Current Ratio | 2.84 | Debt/Eq | 373.87 | LT Debt/Eq | — |
| EPS (ttm) | -1.27 | EPS next Y | -0.86 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 | ROA | -3.04% |
| ROE | -76.41% | ROIC | — | Gross Margin | 31.27% |
| Oper. Margin | -9.86% | Profit Margin | -30.04% | Shs Outstand | 37.47M |
| Shs Float | 19.79M | Short Float | 12.21% | Short Ratio | 19.42 |
| Short Interest | — | 52W High | 8.98 | 52W Low | 4.76 |
| Beta | 0.59 | Avg Volume | 148.00K | Volume | 44.42K |
| Target Price | $9.25 | Recom | None | Prev Close | $7.22 |
| Price | $7.46 | Change | 3.32% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.25
Mean price target
2. Current target
$7.46
Latest analyst target
3. DCF / Fair value
$-13.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.46
Low
$8.50
High
$10.00
Mean
$9.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-04 | init | Keybanc | — → Sector Weight | — |
| 2025-05-21 | init | William Blair | — → Outperform | — |
| 2025-01-03 | reit | Stephens & Co. | Equal-Weight → Equal-Weight | $6 |
| 2024-11-22 | main | Craig-Hallum | Buy → Buy | $10 |
| 2024-09-05 | init | Craig-Hallum | — → Buy | $8 |
| 2024-08-28 | down | Barrington Research | Outperform → Market Perform | — |
| 2023-09-01 | main | Barrington Research | Outperform → Outperform | $10 |
| 2023-09-01 | main | Stephens & Co. | Equal-Weight → Equal-Weight | $9 |
| 2023-06-02 | main | Barrington Research | Outperform → Outperform | $11 |
| 2023-05-24 | main | Barrington Research | Outperform → Outperform | $10 |
| 2023-03-21 | main | Barrington Research | — → Outperform | $8 |
| 2023-03-20 | main | Barrington Research | — → Outperform | $8 |
| 2023-03-20 | down | Stephens & Co. | Overweight → Equal-Weight | $2 |
| 2023-03-17 | reit | Stephens & Co. | — → Overweight | $11 |
- What Contributes to Lifecore Biomedical’s (LFCR) Distinct Competitive Advantage? - Yahoo Finance Fri, 16 Jan 2026 08
- Price-Driven Insight from (LFCR) for Rule-Based Strategy - Stock Traders Daily hu, 19 Feb 2026 14
- Lifecore Biomedical: A Disconnect Between Share Price And Business Progress (LFCR) - Seeking Alpha Sun, 09 Nov 2025 08
- Hedge funds investors in Lifecore Biomedical, Inc. (NASDAQ:LFCR) lost 14% last week but have reaped the benefits of longer-term growth - simplywall.st Fri, 26 Sep 2025 07
- Why Lifecore is being added to Nasdaq’s biotech and pharma index - Stock Titan hu, 18 Dec 2025 08
- Here’s Why Lifecore Biomedical Inc (LFCR) Declined 22% at the End of Q3 - Yahoo Finance hu, 30 Oct 2025 07
- Lifecore Biomedical to Attend Two Upcoming Investor Conferences in November 2025 - Quiver Quantitative ue, 11 Nov 2025 08
- Lifecore Biomedical: Wins Should Blow Previous 'New Business' Estimates Out Of The Water (undefined:LFCR) - Seeking Alpha Wed, 14 Jan 2026 08
- Investors in Lifecore Biomedical (NASDAQ:LFCR) from five years ago are still down 24%, even after 14% gain this past week - simplywall.st Wed, 12 Nov 2025 08
- Earnings call transcript: Lifecore Biomedical Q4 2025 sees stock rise despite EPS miss - Investing.com Fri, 08 Aug 2025 07
- Lifecore Biomedical (LFCR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance Fri, 26 Sep 2025 07
- Lifecore Biomedical: The Turnaround Is Just Getting Started (NASDAQ:LFCR) - Seeking Alpha hu, 01 Jan 2026 08
- KeyBanc maintains Sector Weight rating on Lifecore Biomedical stock - Investing.com Mon, 29 Dec 2025 08
- Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity - simplywall.st ue, 20 Jan 2026 08
- Here’s the Analysis of LifeCore’s (LFCR) Growth Potential - Yahoo Finance Mon, 10 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | OBUS NELSON | Director | — | 2025-07-15 00:00:00 | D |
| 1 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | KIPER CHRISTOPHER S | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-15 00:00:00 | I |
| 2 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | HOUDE KATRINA LOVAS | Director | — | 2025-07-15 00:00:00 | D |
| 3 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | KORENBERG MATTHEW E | Director | — | 2025-07-15 00:00:00 | D |
| 4 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHECHTER JOSHUA E | Director | — | 2025-07-15 00:00:00 | D |
| 5 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | ARYEH JASON M | Director | — | 2025-07-15 00:00:00 | D |
| 6 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | ANTUNES HUMBERTO CALHEIROS | Director | — | 2025-07-15 00:00:00 | D |
| 7 | 19506 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON PAUL HAROLD | Director | — | 2025-07-15 00:00:00 | D |
| 8 | 75000 | nan | — | — | LAKE RYAN DAVID | Chief Financial Officer | — | 2025-07-08 00:00:00 | D |
| 9 | 150000 | nan | — | — | JOSEPHS PAUL | Chief Executive Officer | — | 2025-07-08 00:00:00 | D |
Financials
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.01M | 727.92K | -5.42M | -2.11M |
| TaxRateForCalcs | 0.21 | 0.02 | 0.21 | 0.25 |
| NormalizedEBITDA | -3.98M | -2.29M | -7.35M | 21.20M |
| TotalUnusualItems | -4.83M | 37.84M | -25.82M | -8.36M |
| TotalUnusualItemsExcludingGoodwill | -4.83M | 37.84M | -25.82M | -8.36M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.72M | 9.33M | -64.24M | -15.48M |
| ReconciledDepreciation | 8.03M | 7.95M | 13.18M | 18.06M |
| ReconciledCostOfRevenue | 88.57M | 86.41M | 75.28M | 72.20M |
| EBITDA | -8.81M | 35.56M | -33.17M | 12.84M |
| EBIT | -16.84M | 27.60M | -46.35M | -5.22M |
| NetInterestIncome | -21.84M | -18.09M | -17.58M | -15.47M |
| InterestExpense | 21.84M | 18.09M | 17.58M | 15.47M |
| InterestIncome | 68.00K | 81.00K | 48.00K | |
| NormalizedIncome | -34.90M | -27.79M | -43.84M | -9.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.72M | 12.01M | -99.56M | -116.72M |
| TotalExpenses | 140.87M | 135.45M | 122.99M | 114.70M |
| TotalOperatingIncomeAsReported | -17.25M | -8.84M | -21.80M | -11.79M |
| DilutedAverageShares | 34.82M | 36.66M | 29.97M | 29.51M |
| BasicAverageShares | 34.82M | 30.47M | 29.97M | 29.51M |
| DilutedEPS | -1.27 | 0.32 | -3.41 | -3.30 |
| BasicEPS | -1.27 | 0.40 | -3.41 | -3.29 |
| DilutedNIAvailtoComStockholders | -44.36M | 12.01M | -99.56M | -116.72M |
| NetIncomeCommonStockholders | -44.36M | 12.01M | -99.56M | -116.72M |
| OtherunderPreferredStockDividend | 2.32M | 0.00 | ||
| PreferredStockDividends | 3.32M | |||
| NetIncome | -38.72M | 12.01M | -99.56M | -116.72M |
| NetIncomeIncludingNoncontrollingInterests | -38.72M | 12.01M | -99.56M | -116.72M |
| NetIncomeDiscontinuousOperations | 0.00 | 2.68M | -35.33M | -101.24M |
| NetIncomeContinuousOperations | -38.72M | 9.33M | -64.24M | -15.48M |
| TaxProvision | 43.00K | 183.00K | 308.00K | -5.21M |
| PretaxIncome | -38.67M | 9.51M | -63.93M | -20.69M |
| OtherIncomeExpense | -4.83M | 34.79M | -26.63M | -1.78M |
| OtherNonOperatingIncomeExpenses | -3.00K | -3.05M | -810.00K | 6.57M |
| SpecialIncomeCharges | -5.24M | -1.66M | -25.82M | -8.36M |
| GainOnSaleOfPPE | -6.99M | 0.00 | ||
| GainOnSaleOfBusiness | 0.00 | 2.11M | 0.00 | 0.00 |
| OtherSpecialCharges | 23.74M | 1.11M | ||
| ImpairmentOfCapitalAssets | 28.73M | 0.00 | ||
| RestructuringAndMergernAcquisition | -1.75M | 1.66M | 4.18M | 8.36M |
| GainOnSaleOfSecurity | 409.00K | 39.50M | 1.12M | |
| NetNonOperatingInterestIncomeExpense | -21.84M | -18.09M | -17.58M | -15.47M |
| InterestExpenseNonOperating | 21.84M | 18.09M | 17.58M | 15.47M |
| InterestIncomeNonOperating | 68.00K | 81.00K | 48.00K | |
| OperatingIncome | -12.01M | -7.19M | -19.72M | -3.43M |
| OperatingExpense | 52.30M | 49.04M | 47.70M | 42.50M |
| ResearchAndDevelopment | 8.26M | 8.57M | 8.74M | 7.84M |
| SellingGeneralAndAdministration | 44.05M | 40.46M | 38.97M | 34.66M |
| GrossProfit | 40.30M | 41.85M | 27.98M | 39.07M |
| CostOfRevenue | 88.57M | 86.41M | 75.28M | 72.20M |
| TotalRevenue | 128.87M | 128.26M | 103.27M | 111.27M |
| OperatingRevenue | 128.87M | 128.26M | 103.27M | 111.27M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.03M | 30.56M | 29.51M | 29.51M |
| ShareIssued | 37.03M | 30.56M | 29.51M | 29.51M |
| NetDebt | 122.17M | 116.21M | 82.55M | 137.19M |
| TotalDebt | 130.82M | 128.63M | 112.62M | 150.20M |
| TangibleBookValue | -16.75M | -6.77M | -22.31M | 69.74M |
| InvestedCapital | 131.77M | 135.98M | 97.42M | 226.00M |
| WorkingCapital | 55.50M | 42.16M | 54.59M | -59.91M |
| NetTangibleAssets | -16.75M | -6.77M | -22.31M | 69.74M |
| CapitalLeaseObligations | 387.00K | 3.96M | 10.98M | 12.03M |
| CommonStockEquity | 1.34M | 11.31M | -4.23M | 87.82M |
| TotalCapitalization | 128.34M | 135.04M | 96.83M | 87.82M |
| TotalEquityGrossMinorityInterest | 1.34M | 11.31M | -4.23M | 87.82M |
| StockholdersEquity | 1.34M | 11.31M | -4.23M | 87.82M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -586.00K | -1.36M | |
| OtherEquityAdjustments | -586.00K | -1.36M | ||
| RetainedEarnings | -205.24M | -166.52M | -178.54M | -78.97M |
| AdditionalPaidInCapital | 206.54M | 177.81M | 174.28M | 167.35M |
| CapitalStock | 37.00K | 31.00K | 30.00K | 30.00K |
| CommonStock | 37.00K | 31.00K | 30.00K | 30.00K |
| TotalLiabilitiesNetMinorityInterest | 238.01M | 242.65M | 257.77M | 186.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 207.83M | 203.77M | 218.49M | 10.30M |
| OtherNonCurrentLiabilities | 9.74M | 12.06M | 174.00K | 190.00K |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 2.33M | 3.98M | |
| PreferredSecuritiesOutsideStockEquity | 46.10M | 42.59M | 39.32M | 0.00 |
| DerivativeProductLiabilities | 24.99M | 25.40M | 64.90M | 0.00 |
| NonCurrentDeferredLiabilities | 5.25M | 3.32M | 126.00K | 6.14M |
| NonCurrentDeferredRevenue | 4.70M | 2.94M | ||
| NonCurrentDeferredTaxesLiabilities | 543.00K | 380.00K | 126.00K | 6.14M |
| LongTermDebtAndCapitalLeaseObligation | 127.00M | 123.72M | 110.77M | 7.66M |
| LongTermCapitalLeaseObligation | 4.94M | 9.71M | 7.66M | 20.36M |
| LongTermDebt | 127.00M | 123.72M | 101.06M | 97.58M |
| CurrentLiabilities | 30.18M | 38.87M | 39.29M | 176.58M |
| OtherCurrentLiabilities | 2.17M | 2.37M | 4.74M | 42.64M |
| CurrentDeferredLiabilities | 3.42M | 2.11M | 4.05M | 919.00K |
| CurrentDeferredRevenue | 3.42M | 2.11M | 4.05M | 919.00K |
| CurrentDebtAndCapitalLeaseObligation | 3.82M | 4.91M | 1.85M | 142.55M |
| CurrentCapitalLeaseObligation | 387.00K | 3.96M | 1.27M | 4.37M |
| CurrentDebt | 3.44M | 943.00K | 580.00K | 138.18M |
| OtherCurrentBorrowings | 3.44M | 943.00K | 580.00K | 98.18M |
| LineOfCredit | 0.00 | 40.00M | 29.00M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.14M | 6.17M | 4.14M | 8.94M |
| PayablesAndAccruedExpenses | 14.63M | 23.31M | 29.24M | 19.43M |
| CurrentAccruedExpenses | 1.91M | 3.51M | 7.14M | 6.48M |
| Payables | 12.72M | 19.80M | 22.10M | 12.95M |
| OtherPayable | 4.50M | 3.47M | ||
| AccountsPayable | 8.22M | 16.33M | 22.10M | 12.95M |
| TotalAssets | 239.34M | 253.96M | 253.54M | 274.70M |
| TotalNonCurrentAssets | 153.66M | 172.93M | 159.67M | 158.03M |
| OtherNonCurrentAssets | 6.58M | 5.68M | 2.92M | 15.73M |
| InvestmentsAndAdvances | 45.10M | |||
| OtherInvestments | 45.10M | |||
| GoodwillAndOtherIntangibleAssets | 18.08M | 18.08M | 18.08M | 18.08M |
| OtherIntangibleAssets | 4.20M | 4.20M | 4.20M | 4.20M |
| Goodwill | 13.88M | 13.88M | 13.88M | 13.88M |
| NetPPE | 129.01M | 149.16M | 138.67M | 124.22M |
| AccumulatedDepreciation | -57.41M | -50.33M | -57.01M | -46.86M |
| GrossPPE | 186.42M | 199.50M | 195.68M | 171.09M |
| Leases | 0.00 | 4.02M | 4.02M | 6.46M |
| ConstructionInProgress | 47.76M | 61.95M | 45.59M | 26.89M |
| OtherProperties | 2.44M | 4.28M | 5.55M | 17.10M |
| MachineryFurnitureEquipment | 71.19M | 70.93M | 77.36M | 72.55M |
| BuildingsAndImprovements | 63.73M | 62.87M | 60.69M | 58.36M |
| LandAndImprovements | 3.74M | 3.74M | 3.74M | 3.71M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 85.68M | 81.03M | 93.88M | 116.67M |
| OtherCurrentAssets | 1.45M | 1.44M | 4.92M | 2.05M |
| AssetsHeldForSaleCurrent | 0.00 | 39.31M | 37.62M | |
| PrepaidAssets | 7.05M | 5.04M | ||
| Inventory | 32.29M | 39.98M | 40.84M | 36.00M |
| InventoriesAdjustmentsAllowances | -1.42M | -384.00K | ||
| FinishedGoods | 13.38M | 14.92M | 13.14M | 13.40M |
| WorkInProcess | 8.74M | 11.91M | 10.35M | 7.12M |
| RawMaterials | 10.17M | 13.14M | 17.73M | 15.49M |
| Receivables | 43.67M | 31.15M | 29.02M | 38.31M |
| OtherReceivables | 6.98M | 4.07M | ||
| NotesReceivable | 8.00M | 0.00 | ||
| AccountsReceivable | 28.69M | 27.08M | 29.02M | 38.31M |
| AllowanceForDoubtfulAccountsReceivable | -1.35M | -711.00K | -485.00K | -65.00K |
| GrossAccountsReceivable | 30.04M | 27.80M | 29.51M | 48.24M |
| CashCashEquivalentsAndShortTermInvestments | 8.27M | 8.46M | 19.09M | 991.00K |
| CashAndCashEquivalents | 8.27M | 8.46M | 19.09M | 991.00K |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.62M | -18.14M | -38.92M | -52.53M |
| RepaymentOfDebt | -146.69M | -147.42M | -178.33M | -130.52M |
| IssuanceOfDebt | 130.97M | 149.59M | 181.45M | 75.11M |
| IssuanceOfCapitalStock | 23.85M | 0.00 | 42.90M | 0.00 |
| CapitalExpenditure | -13.41M | -18.39M | -21.48M | -29.94M |
| InterestPaidSupplementalData | 1.91M | 2.73M | 31.02M | 16.89M |
| IncomeTaxPaidSupplementalData | 46.00K | 72.00K | 23.00K | 441.00K |
| EndCashPosition | 8.27M | 8.46M | 19.09M | 1.64M |
| BeginningCashPosition | 8.46M | 19.09M | 1.64M | 1.29M |
| ChangesInCash | -197.00K | -10.63M | 17.45M | 348.00K |
| FinancingCashFlow | 6.42M | 7.51M | 39.70M | -57.02M |
| CashFlowFromContinuingFinancingActivities | 6.42M | 7.51M | 39.70M | -57.02M |
| NetOtherFinancingCharges | -435.00K | 4.77M | -6.32M | -1.61M |
| ProceedsFromStockOptionExercised | -1.27M | 572.00K | 0.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | 38.08M | 0.00 | 0.00 |
| PreferredStockIssuance | 0.00 | 38.08M | 0.00 | 0.00 |
| NetCommonStockIssuance | 23.85M | 0.00 | 4.82M | 0.00 |
| CommonStockIssuance | 23.85M | 0.00 | 4.82M | 0.00 |
| NetIssuancePaymentsOfDebt | -15.72M | 2.17M | 3.12M | -55.41M |
| NetShortTermDebtIssuance | -54.64M | -44.11M | -148.40M | |
| ShortTermDebtPayments | -54.64M | -44.11M | -148.40M | |
| ShortTermDebtIssuance | 31.45M | 55.11M | 100.00M | |
| NetLongTermDebtIssuance | -15.72M | 2.17M | 3.12M | -55.41M |
| LongTermDebtPayments | -146.69M | -147.42M | -178.33M | -130.52M |
| LongTermDebtIssuance | 130.97M | 149.59M | 181.45M | 75.11M |
| InvestingCashFlow | -6.42M | -18.39M | -4.81M | 79.96M |
| CashFlowFromContinuingInvestingActivities | -6.42M | -18.39M | -4.81M | 79.96M |
| NetOtherInvestingChanges | -9.84M | |||
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 45.10M | 0.00 |
| SaleOfInvestment | 0.00 | 0.00 | 45.10M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 16.67M | 73.50M | 0.00 |
| SaleOfBusiness | 0.00 | 16.67M | 73.50M | 0.00 |
| PurchaseOfBusiness | 0.00 | -9.84M | 0.00 | |
| NetPPEPurchaseAndSale | -6.42M | -18.39M | -21.48M | -28.80M |
| SaleOfPPE | 7.00M | 0.00 | 0.00 | 1.14M |
| PurchaseOfPPE | -13.41M | -18.39M | -21.48M | -29.94M |
| OperatingCashFlow | -206.00K | 257.00K | -17.44M | -22.59M |
| CashFlowFromContinuingOperatingActivities | -206.00K | 257.00K | -17.44M | -22.59M |
| ChangeInWorkingCapital | -4.70M | -3.70M | 19.79M | -3.10M |
| ChangeInOtherWorkingCapital | -179.00K | 6.08M | -18.00K | 428.00K |
| ChangeInOtherCurrentAssets | 378.00K | 2.85M | 2.16M | -689.00K |
| ChangeInPayablesAndAccruedExpense | -7.59M | -5.02M | 15.55M | 5.92M |
| ChangeInAccruedExpense | -5.92M | 1.65M | -492.00K | -3.42M |
| ChangeInPayable | -1.67M | -6.68M | 16.04M | 9.34M |
| ChangeInAccountPayable | -1.67M | -6.68M | 16.04M | 9.34M |
| ChangeInPrepaidAssets | 2.16M | -602.00K | 8.28M | |
| ChangeInInventory | 7.69M | 862.00K | -14.81M | -2.18M |
| ChangeInReceivables | -5.17M | -2.39M | 10.82M | -6.14M |
| ChangesInAccountReceivables | -2.26M | -3.26M | 10.82M | -6.14M |
| OtherNonCashItems | 17.65M | 17.27M | 1.07M | -426.00K |
| StockBasedCompensation | 10.16M | 6.20M | 3.61M | 2.61M |
| ProvisionandWriteOffofAssets | 263.00K | 163.00K | -14.00K | 940.00K |
| AssetImpairmentCharge | 0.00 | 1.30M | 78.15M | 0.00 |
| DeferredTax | 163.00K | 357.00K | -6.83M | -7.87M |
| DeferredIncomeTax | 163.00K | 357.00K | -6.83M | -7.87M |
| DepreciationAmortizationDepletion | 8.03M | 7.95M | 13.18M | 18.06M |
| DepreciationAndAmortization | 8.03M | 7.95M | 13.18M | 18.06M |
| Depreciation | 8.03M | 7.95M | 13.29M | 17.88M |
| OperatingGainsLosses | 7.37M | -39.48M | 42.65M | 5.67M |
| GainLossOnInvestmentSecurities | -409.00K | -39.50M | 11.47M | |
| GainLossOnSaleOfPPE | 7.78M | 18.00K | 38.00K | 5.34M |
| GainLossOnSaleOfBusiness | 0.00 | 18.87M | 336.00K | 0.00 |
| NetIncomeFromContinuingOperations | -38.72M | 12.01M | -99.56M | -116.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LFCR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|